THEORETICAL AND PRACTICAL ASPECTS OF 18F-FDG PET
Abstract
The incidence of oncological diseases has become very high in the last decade, whether we refer to more or less developed countries. The incidence of the oncologic disease continue to increases in spite of substantial progress in the development of medicine and medical technologies. At the same time, an efficient treatment depends on an accurate and timely diagnostic. A solution for precise diagnostic is provided by nuclear medicine through the positron emission tomography (PET) technique, which allows an accurate evaluation of metabolism in different organs and tissues. PET permits timely identification of functional disturbances underlying the development of the disease. In the past decade’s positron emission (PET) 18F-fluoro-deoxy-glucose (18F-FDG) has been used to evaluate tumor patients. Evaluation of distribution, spread and proliferation of cancerous cells is considered to be useful for therapeutic guidance and therapeutic effect assessment. Thus, radiolabeled molecules, such as the [18F]-2-Fluoro-2-deoxy-β-D-glucopyranose has been developed. Fluorine-18 is a short-lived positron emitting isotope which finds a massive use as a label for radiotracers used with the molecular imaging technique of PET. The Quality Control (QC) process concerns all the mechanisms, actions and tools developed to detect the presence of errors in a production batch. This review focuses on the importance of 18F-FDG and our goal was to present some theoretical and practical aspects of the 18F-FDG synthesis and what parameters and how should they be evaluated in QC laboratories.
References
2. Moeendarbari S, Tekade R, Mulgaonkar A, et al. Theranostic nano seeds for efficacious internal radiation therapy of unresectable solid tumors. Scientific reports 2016; 6, 20614.
3. Tekade RK, Sun X. The Warburg effect and glucose-derived cancer theranostics. Drug Discov Today 2017; 22(11): 1637-1653.
4. Apostolova I, Florian W, Winfried B. Imaging of tumor metabolism using positron emission tomog-raphy (PET). In: Metabolism in Cancer. Springer, Cham, 2016, 177-205.
5. Caitlund QD, Christopher PP, Tai TC, Neelam K, Simon JL. Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation. Am J Nucl Med Mol Imaging 2018; 8(3): 200-227.
6. Feng H, Wang X, Chen J, et al. Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG. Contrast media & molecular imaging, 2019.
7. Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism, Nat Rev Cancer 2011; 11(5): 325-337.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
9. Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer 2016; 16(10): 635.
10. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med 2013; 34(2-3): 121-38.
11. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000; 41(4): 661-681.
12. Granov A, Tiutin L, Schwarz T, editors. Positron emission tomography. Springer Science & Business Media, 2013.
13. IAEA. Radioisotopes and Radiopharmaceuticals Series No. 3. Cyclotron Produced Radionuclides: Guidance on Facility Design and Production of [18F] Fluorodeoxyglucose (FDG), Vienna, 2012.
14. Coenen HH. Fluorine-18 labeling methods: features and possibilities of basic reactions. In: PET chemistry. Springer, Berlin, Heidelberg, 2007, 15-50.
15. Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. Journal of nu-clear medicine: official publication, Society of Nuclear Medicine 1986; 27(2): 235-238.
16. Pacák J, Točík Z, Černý M. Synthesis of 2-deoxy-2-fluoro-D-glucose. Journal of the Chemical Society D: Chemical Communications 1969; (2): 77-77.
17. Ido T, Wan CN, Casella V, et al. Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Label Compd Ra-diopharm 1978; 14(2): 175-183.
18. Cai L, Lu S, Pike VW. Chemistry with [18F] Fluoride Ion. Eur J Org Chem 2008, 2853-2873.
19. Füchtner F, Steinbach J, Mäding P, Johannsen B. Basic hydrolysis of 2-[18F] fluoro-1, 3, 4, 6-tetra-O-acetyl-D-glucose in the preparation of 2-[18F] fluoro-2-deoxy-D-glucose. Appl Radiat Isot 1996; 47(1): 61-66.
20. Lemaire C, Damhaut Ph, Lauricella B, et al. Synthesis of [18F] FDG with alkaline hydrolysis on a low polarity solid phase support. J Label Compd Radiopharm 1997; 40: 256-257.
21. Mosdzianowski C, Lemaire C, Simoens F, Aerts J, Morelle JL, Luxen A. Epimerization study on [18F] FDG produced by an alkaline hydrolysis on solid support under stringent conditions. Appl Radiat Isot 2002; 56(6): 871-875.
22. Fludeoxyglucose (18F) injection. In: European Pharmacopeia. 9th ed. Strasbourg, France: European Directorate for the Quality of the Medicines, 2017.
23. Fang P, Jacobson M, Franci X, Smith R, Lowe V. Comparison of FASTlab and TRACERLAB FX synthesizers. J Nucl Med 2007; 48(Suppl 2): 325P.
24. Jacobson MS, Dankwart HR, Mahoney D.W. Radiolysis of 2-[18F] fluoro-2-deoxy-d-glucose ([18F] FDG) and the role of ethanol and radioactive concentration. Appl Radiat Isot 2009, 67(6): 990-995.
25. Grainger HS. The role of the pharmacopoeia in the control of pharmaceutical preparations. Ann Ist Super Sanità 1975; 11 (3-4): 305-313.
26. Good Manufacturing Practices for Pharmaceutical Products. In: WHO Expert Committee 520 on Specifications for Pharmaceutical Preparations. Thirty-second report. Geneva, World 521 Health Organization, 2014, Annex 2 (WHO Technical Report Series, No. 986.
27. Shukla AK, Kumar U. Positron emission tomography: An overview. J Med Phys 2006; 31(1): 13-21.
28. Andreyev A, Celler A. Dual-isotope PET using positron-gamma emitters. Phys Med Biol 2011; 56(14): 4539.
29. Yu S. Review of 18F-FDG synthesis and quality control. Biomed Imaging Interv J 2006; 2(4): e57.
30. Touchstone JC. Practice of thin layer chromatography. John Wiley & Sons, 1992.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
